Prelude Therapeutics (PRLD) is scheduled to report Q1 earnings on May 5, 2026. Analysts estimate EPS of $-0.29 and quarterly revenue of N/A.

In the most recent quarter (Q4), Prelude Therapeutics reported EPS of $-0.20, beating estimates of $-0.24 by 0.17%. Revenue came in at $5.64M, missing the estimate of $20.50M by 0.72%.

Prelude Therapeutics has beaten EPS estimates in 6 consecutive quarters.

Over the last 4 quarters, Prelude Therapeutics has averaged an EPS surprise of 0.15% and a revenue surprise of 0.72%.